DelMar Pharmaceuticals, Inc. (OTCQB:DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer, specifically for glioblastoma.
DelMar's lead product candidate is VAL-083, which represents a "first in class" small-molecule chemotherapeutic. VAL-083 has been assessed in multiple clinical studies sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers including lung, brain, cervical, ovarian tumors and leukemia. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer but has not been approved for...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: